Trials / Completed
CompletedNCT03593525
SPARK Symptom Screening and Feedback to Providers
A Randomized Controlled Trial of Symptom Screening by Children With Cancer and Feedback to Providers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 345 (actual)
- Sponsor
- The Hospital for Sick Children · Academic / Other
- Sex
- All
- Age
- 8 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Supportive care Prioritization, Assessment and Recommendations for Kids (SPARK) is a web-based application which builds upon the Symptom Screening in Pediatrics Tool (SSPedi) and consists of two components: (1) a symptom screening component centered on SSPedi; and (2) a supportive care clinical practice guideline (CPG) component. This proposal is a randomized controlled trial that compares daily completion of SSPedi via SPARK for 5 days with symptom feedback to healthcare providers compared with standard of care
Detailed description
Participants will be children with cancer or hematopoietic stem cell transplantation (HSCT) recipients who are 8-18 years of age and who can understand English, and who are expected to be in hospital or in clinic daily for 5 days. This will be a multi-center RCT in which we will randomize children to either undergo daily symptom screening for 5 days with symptom reports provided to the healthcare team or standard of care. The primary outcome will be the self-reported day 5 total SSPedi score (range 0-60; higher worse). Secondary outcomes will be the day 5 self-reported individual symptom, pain and QoL scores, and documentation of symptoms and provision of interventions for symptoms over the 5 day trial. We will enroll 345 participants over 4 years from 7 Canadian centers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | SPARK | see above |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2023-09-16
- Completion
- 2023-09-17
- First posted
- 2018-07-20
- Last updated
- 2025-08-08
- Results posted
- 2025-07-02
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03593525. Inclusion in this directory is not an endorsement.